PSMB9 and pulmonary emphysema: To assess the therapeutic potential of immunoproteasome in polarized macrophages as a target for emphysema, we intratracheally administered ONX‐0914, a selective inhibitor of immunoproteasome subunits LMP7 and LMP2, into the lungs of emphysema‐induced mice three times a week for four consecutive weeks, beginning one day after the initiation of LPS + Elastase treatment, at various dosages (1, 2.5, and 5 mg kg−1) (Figure 2A).